Pharmaceutics and parenting inspired Melanie A. Felmlee, PhD, assistant professor of pharmaceutics and medicinal chemistry, to pursue a grant for research of monocarboxylate transporters. Dr. Felmlee was awarded the 2017 American Association of Colleges of Pharmacy New Investigator Award (NIA) for her proposal entitled “Maturation and spatial expression of intestinal MCT1 in obesity.”
Dr. Felmlee has been studying transporters for the past nine years. This research builds on her previous research of monocarboxylate transporter 1 (MCT1). In her previous research studies, Dr. Felmlee has investigated the behavior of this transporter in the kidney and liver. She shares, “The pediatric part honestly came from my kids,” said Dr. Femlee. “As parents, we want to figure out how kids work.”
“The overall objective of this study is to investigate the maturation and spatial expression of intestinal MCT1 in obesity to improve our understanding of its developmental regulation,” Dr. Felmlee said. She will use the $10,000 in funding from the award to investigate how MCT1 behaves in different regions of the intestine. Throughout the research process she will be assisted by Michael Ng ’20.
She explains that the International Transporter Consortium identified the need for additional research on MCT1. “Monocarboxylate transporters are involved in intestinal drug absorption, yet maturation and spatial expression data are lacking in the literature,” Dr. Felmlee said.
In addition to a patient’s age, obesity could affect drug pharmacokinetics and toxicity. She elaborates, “Alterations in drug absorption, distribution, metabolism and elimination (ADME) due to physiological changes resulting from childhood obesity can influence drug exposure leading to lack of efficacy or toxicity. Physiological alterations in obesity include changes in the expression of drug transporter and metabolic enzymes leading to altered liver function, kidney function and intestinal absorption.”
“The prevalence of childhood obesity has reached epidemic proportions, with 42 million children worldwide under the age of five considered overweight,” Dr. Felmlee explains. “Obese children are more likely to require pharmacotherapy, so it is crucial to optimize therapeutic interventions to avoid lack of efficacy or toxicity.”
The goal of this study is to contribute to the understanding of MCT1 so that health care providers can optimize therapeutic strategies in obese pediatric patients by accounting for variations in drug absorption. In addition, a greater understanding of transporters can pave the way for personalized treatment plans for both normal weight and obese pediatric patients. Dr. Felmlee believes that understanding MCT1 “is one small piece” in the development of personalized medicine. “Give them an optimized therapy, the right treatment at the right time,” Dr. Felmlee said.
This grant holds special significance as this is the first external funding Dr. Felmlee has received. The AACP New Investigator Award is tailored to pharmacy faculty who are at the start of their career as researchers. She shares what receiving this grant means to her personally: “It’s a confidence booster. Putting together a grant proposal is difficult and time consuming.” Being awarded the NIA is “validation that someone believes in the research you are doing and believes in you as a researcher.”
Since joining the Pacific faculty in 2015, Dr. Felmlee has found the atmosphere of the School to be supportive and encouraging. She appreciates the friendly, collaborative environment, as well as their balanced approach to teaching and research. She elaborates, “We are really well balanced. I feel supported to teach and given the time and resources to pursue research.” She shares a memory of an interaction with Dean Phillip Oppenheimer, PharmD, where he acknowledged one of her recent accomplishments. “Dean Oppenheimer saw me washing out my coffee mug and congratulated me,” Dr. Felmlee said. “I love those little things.”